There are three stages of trails starting with stage I which is dose escalation of the investigational new drug (IND) to determine the “therapeutic” dose to administer and in expanded phase III trials which often times are randomized, double blinded. The same trial does not have all three of these phases at the same time. When phase I finished and meets the objective, it goes to phase II. When the objectives are met successfully, it the is expanded to stage III.

It is possible that an IND can be used in different trials where it may be tested alone as monotherapy, in combination with another IND, or combined with a standard of care. This is the case with RMC-6236 and why you will find it in various phases. You will not find it standing alone in three different phases. You will have to see what is available in how it is configured and in what phase, research it for the benefits and risks in that phase and make an informed decision.